Contact us

Media

Media Contacts & Information

This information is intended for journalists located in the UK only. Click here for general enquiries.

Contact information for UK journalists:
Email: enquiries@taurx.com

Filter:

Sort by:

TauRx’s hydromethylthionine mesylate (HMTM) demonstrates significant reduction in neurodegeneration in Alzheimer’s Disease (AD)

2 December 2022

LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development

14 November 2022

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

TauRx welcomes new Chief Medical Officer, Dr Richard Stefanacci

28 September 2022

TauRx Pharmaceuticals organises Information Meeting for Alzheimer Europe members

Initial Data of LUCIDITY Study

1 2 3 4

Further reading

Company history

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Environmental, Social and Governance at TauRx

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments